Candel Therapeutics Announces Positive Phase 3 Results for CAN-2409 in Prostate Cancer and Presents New NSCLC Data at SITC 2025 Annual Meeting
Reuters
Oct 03, 2025
Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 3 Results for CAN-2409 in Prostate Cancer and Presents New NSCLC Data at SITC 2025 Annual Meeting
Candel Therapeutics Inc. has announced that it will present new insights from its enLIGHTEN™ Discovery Platform and additional data from its CAN-2409 (aglatimagene besadenovec) program for non-small cell lung cancer (NSCLC) at the Society for Immunotherapy of Cancer's $(SITC)$ 40th Anniversary Annual Meeting, scheduled for November 5-9, 2025, in National Harbor, Maryland. The company will share results from two accepted poster presentations, including analyses on the differential immune response to CAN-2409 plus valacyclovir in NSCLC. In addition, Candel Therapeutics' President and CEO, Dr. Paul Peter Tak, will present phase 3 clinical trial data of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer during an invited faculty session and panel discussion. The results from these studies will be presented at the upcoming meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539284-en) on October 03, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.